Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants
Authors
Keywords
-
Journal
Human Vaccines & Immunotherapeutics
Volume 12, Issue 5, Pages 1300-1310
Publisher
Informa UK Limited
Online
2016-02-02
DOI
10.1080/21645515.2015.1136040
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults
- (2015) Roger Baxter et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Comparative Assessment of a Single Dose and a 2-Dose Vaccination Series of a Quadrivalent Meningococcal CRM-Conjugate Vaccine (MenACWY-CRM) in Children 2–10 Years of Age
- (2015) William Johnston et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines
- (2015) Timo Vesikari et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice
- (2015) Rolando Pajon et al. VACCINE
- Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination
- (2015) Stan L. Block et al. VACCINE
- Serum bactericidal antibody assays – The role of complement in infection and immunity
- (2015) E.D.G. McIntosh et al. VACCINE
- Persistent low carriage of serogroup A Neisseria meningitidistwo years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac
- (2014) Paul A Kristiansen et al. BMC INFECTIOUS DISEASES
- Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers
- (2014) Miguel Tregnaghi et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Antibody Persistence and Booster Response of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents
- (2014) Roger Baxter et al. JOURNAL OF PEDIATRICS
- Antibody Persistence After Primary and Booster Doses of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents
- (2014) Roger Baxter et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study
- (2013) Charissa Borja-Tabora et al. BMC INFECTIOUS DISEASES
- Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study
- (2013) DM Daugla et al. LANCET
- One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine Is Immunogenic in 9- to 12-Month-Old Children
- (2013) Nicola P. Klein et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Effectiveness of meningococcal serogroup C vaccine programmes
- (2013) Ray Borrow et al. VACCINE
- Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT)
- (2012) Lars Østergaard et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Antibody Persistence and Response to a Booster Dose of a Quadrivalent Conjugate Vaccine for Meningococcal Disease in Adolescents
- (2012) Robert M. Jacobson et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers
- (2012) Timo Vesikari et al. Human Vaccines & Immunotherapeutics
- Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents
- (2011) Christopher J. Gill et al. Human vaccines & immunotherapeutics
- Safety and Immunogenicity of a Novel Quadrivalent Meningococcal CRM-conjugate Vaccine Given Concomitantly With Routine Vaccinations in Infants
- (2011) Nicola P. Klein et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Meningococcal carriage by age: a systematic review and meta-analysis
- (2010) Hannah Christensen et al. LANCET INFECTIOUS DISEASES
- Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of age
- (2010) Scott A. Halperin et al. VACCINE
- Ex Vivo Model of Meningococcal Bacteremia Using Human Blood for Measuring Vaccine-Induced Serum Passive Protective Activity
- (2009) J. S. Plested et al. Clinical and Vaccine Immunology
- Investigation of Different Group A Immunoassays following One Dose of Meningococcal Group A Conjugate Vaccine or A/C Polysaccharide Vaccine in Adults
- (2009) H. Findlow et al. Clinical and Vaccine Immunology
- Quadrivalent Meningococcal Vaccination of Adults: Phase III Comparison of an Investigational Conjugate Vaccine, MenACWY-CRM, with the Licensed Vaccine, Menactra
- (2009) K. S. Reisinger et al. Clinical and Vaccine Immunology
- Global epidemiology of meningococcal disease
- (2009) Lee H. Harrison et al. VACCINE
- Vaccine-Induced Opsonophagocytic Immunity to Neisseria meningitidis Group B
- (2008) J. S. Plested et al. Clinical and Vaccine Immunology
- Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants
- (2008) Matthew D. Snape et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started